‹ ›
MYP_104624
← PREVIOUS NEXT → BACK
Basic Information
mHR2(derived from SARS-CoV spike protein heptad repeat)
Antimicrobial
Antiviral
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition ▸ Fusion inhibitor
Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor
Standard
39 amino acids
C207H337N51O67S
Standard
Sequence
DLSLDFEKLNVTLLDLTYEMNRIQDAIKKLNESYINLKE
Physicochemical Analysis
4644.26 Da
4.63
-3.22
-3.45
-0.0827
-0.43
0.78
-0.07
4.87
120.00
0.0769
2980.00
2980.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
1970.33
-15.45
66.0
65.0
164.0
326.0
3.0
43.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0290909 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Antiviral
PaperPubMed PMID: 15150417 PMID15150417 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/15150417/
RECORD: Rec_0295965 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-SARS-CoV Fusion inhibition
SARS-CoV | Vero cells
50 μM
EC50
Mammalian: 1.1 h; Yeast: 3 min; E. coli: >10 h
PaperSevere acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. | Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ. | Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60. | DOI:10.1073/pnas.0400576101 | PMID:15150417 PMID15150417 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/15150417/
RECORD: Rec_0303643 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Fusion inhibition
murine coronavirus | Vero cells
0.9±0.1 μM
EC50
Mammalian: 1.1 h; Yeast: 3 min; E. coli: >10 h
PaperSevere acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. | Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ. | Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60. | DOI:10.1073/pnas.0400576101 | PMID:15150417 PMID15150417 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/15150417/
RECORD: Rec_0367947 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-SARS-CoV Fusion inhibition
SARS-CoV | 118 cells
50 μM
EC50
Mammalian: 1.1 h; Yeast: 3 min; E. coli: >10 h
PaperSevere acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. | Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ. | Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60. | DOI:10.1073/pnas.0400576101 | PMID:15150417 PMID15150417 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/15150417/
FIRST PREV 1 2 3
Showing 4 records on this page · Page 3 of 3